The Clinical Value of Serum Sirtuin-1 Concentration in the Diagnosis of Metabolic Dysfunction-associated Steatotic Liver Disease

Overview

Journal BMC Gastroenterol

Publisher Biomed Central

Date 2025 Jan 23

PMID 39844087

Authors

Farshad Amirkhizi

Mahdiyeh Taghizadeh

Banafshe Khalese-Ranjbar

Soudabeh Hamedi-Shahraki

Somayyeh Asghari

Affiliations

Soon will be listed here.

Abstract

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most prevalent chronic liver disease and can affect individuals without producing any symptoms. We aimed to explore the value of serum sirtuin-1 (Sirt-1) in the diagnosis of MASLD.

Methods: This case-control study analyzed data collected from 190 individuals aged 20 to 60 years. Anthropometric parameters, demographic information, and serum biochemical variables-including glycemic parameters, lipid profiles, liver enzymes, and Sirt-1 levels-were assessed. The correlation between serum Sirt-1 and biochemical variables was examined using Pearson's correlation coefficient. Receiver operating characteristic (ROC) curve analysis was employed to evaluate the diagnostic value of serum Sirt-1 in the context of MASLD.

Results: Serum Sirt-1 levels was significantly lower in the MASLD group (p < 0.001) and was inversely correlated with serum insulin (r = -0.163, p = 0.025), HOMA-IR (r = -0.169, p = 0.020) and triglyceride (r = -0.190, p = 0.009) and positively correlated with serum levels of high-density lipoprotein cholesterol (HDL-C) (r = 0.214, p = 0.003). The area under the curve (AUC) of Sirt-1 to predict the presence of MASLD was 0.76 (p < 0.001, 95% CI: 0.69, 0.82) with a sensitivity of 78.9, specificity of 61.1, positive predictive value (PPV) of 67.0%, and negative predictive value (NPV) of 74.0%. The optimal cutoff, determined using Youden's index, was 23.75 ng/mL. This indicates that serum Sirt-1 levels below 23.75 ng/mL may be indicative of MASLD.

Conclusions: The present study demonstrated that serum Sirt-1 levels were significantly lower in patients with MASLD. Furthermore, these levels were correlated with various metabolic parameters, including insulin resistance and the serum lipid profile. A serum Sirt-1 level below the cutoff of 23.75 ng/mL exhibited a significant association with the presence of MASLD, suggesting its potential utility in identifying patients with this condition.

References

Itoh N . FGF21 as a Hepatokine, Adipokine, and Myokine in Metabolism and Diseases. Front Endocrinol (Lausanne). 2014; 5:107. PMC: 4083219. DOI: 10.3389/fendo.2014.00107. View

Vozarova B, Stefan N, Lindsay R, Saremi A, Pratley R, Bogardus C . High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes. Diabetes. 2002; 51(6):1889-95. DOI: 10.2337/diabetes.51.6.1889. View

Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M . Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes. 2001; 50(8):1844-50. DOI: 10.2337/diabetes.50.8.1844. View

Whitfield J . Gamma glutamyl transferase. Crit Rev Clin Lab Sci. 2001; 38(4):263-355. DOI: 10.1080/20014091084227. View

Daneshi-Maskooni M, Keshavarz S, Qorbani M, Mansouri S, Alavian S, Badri-Fariman M . Green cardamom increases Sirtuin-1 and reduces inflammation in overweight or obese patients with non-alcoholic fatty liver disease: a double-blind randomized placebo-controlled clinical trial. Nutr Metab (Lond). 2018; 15:63. PMC: 6156864. DOI: 10.1186/s12986-018-0297-4. View

Yamagata K, Yoshizawa T . Transcriptional Regulation of Metabolism by SIRT1 and SIRT7. Int Rev Cell Mol Biol. 2018; 335:143-166. DOI: 10.1016/bs.ircmb.2017.07.009. View

Wang Y . Molecular Links between Caloric Restriction and Sir2/SIRT1 Activation. Diabetes Metab J. 2014; 38(5):321-9. PMC: 4209345. DOI: 10.4093/dmj.2014.38.5.321. View

Purushotham A, Schug T, Xu Q, Surapureddi S, Guo X, Li X . Hepatocyte-specific deletion of SIRT1 alters fatty acid metabolism and results in hepatic steatosis and inflammation. Cell Metab. 2009; 9(4):327-38. PMC: 2668535. DOI: 10.1016/j.cmet.2009.02.006. View

Fisher F, Chui P, Nasser I, Popov Y, Cunniff J, Lundasen T . Fibroblast growth factor 21 limits lipotoxicity by promoting hepatic fatty acid activation in mice on methionine and choline-deficient diets. Gastroenterology. 2014; 147(5):1073-83.e6. PMC: 4570569. DOI: 10.1053/j.gastro.2014.07.044. View

10.

Bechmann L, Hannivoort R, Gerken G, Hotamisligil G, Trauner M, Canbay A . The interaction of hepatic lipid and glucose metabolism in liver diseases. J Hepatol. 2011; 56(4):952-64. DOI: 10.1016/j.jhep.2011.08.025. View

11.

Verma S, Jensen D, Hart J, Mohanty S . Predictive value of ALT levels for non-alcoholic steatohepatitis (NASH) and advanced fibrosis in non-alcoholic fatty liver disease (NAFLD). Liver Int. 2013; 33(9):1398-405. DOI: 10.1111/liv.12226. View

12.

Yu E, Golshan S, Harlow K, Angeles J, Durelle J, Goyal N . Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity. J Pediatr. 2018; 207:64-70. PMC: 6440815. DOI: 10.1016/j.jpeds.2018.11.021. View

13.

Li Y, Xu S, Giles A, Nakamura K, Lee J, Hou X . Hepatic overexpression of SIRT1 in mice attenuates endoplasmic reticulum stress and insulin resistance in the liver. FASEB J. 2011; 25(5):1664-79. PMC: 3079300. DOI: 10.1096/fj.10-173492. View

14.

Li Y, Wong K, Walsh K, Gao B, Zang M . Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice. J Biol Chem. 2013; 288(15):10490-504. PMC: 3624431. DOI: 10.1074/jbc.M112.429852. View

15.

Song Y, Lee S, Jang Y, Park H, Kim J, Lee Y . Association between low SIRT1 expression in visceral and subcutaneous adipose tissues and metabolic abnormalities in women with obesity and type 2 diabetes. Diabetes Res Clin Pract. 2013; 101(3):341-8. DOI: 10.1016/j.diabres.2013.07.002. View

16.

Ponugoti B, Kim D, Xiao Z, Smith Z, Miao J, Zang M . SIRT1 deacetylates and inhibits SREBP-1C activity in regulation of hepatic lipid metabolism. J Biol Chem. 2010; 285(44):33959-70. PMC: 2962496. DOI: 10.1074/jbc.M110.122978. View

17.

Cobbina E, Akhlaghi F . Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211. PMC: 5576152. DOI: 10.1080/03602532.2017.1293683. View

18.

Younossi Z, Anstee Q, Marietti M, Hardy T, Henry L, Eslam M . Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2017; 15(1):11-20. DOI: 10.1038/nrgastro.2017.109. View

19.

Hong J, Kim B, Choo H, Park J, Yi J, Yu D . Mitochondrial complex I deficiency enhances skeletal myogenesis but impairs insulin signaling through SIRT1 inactivation. J Biol Chem. 2014; 289(29):20012-25. PMC: 4106319. DOI: 10.1074/jbc.M114.560078. View

20.

Marchesini G, Brizi M, Morselli-Labate A, Bianchi G, Bugianesi E, McCullough A . Association of nonalcoholic fatty liver disease with insulin resistance. Am J Med. 1999; 107(5):450-5. DOI: 10.1016/s0002-9343(99)00271-5. View